November 1, 2020Open Access

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

We confirmed the association between baseline steroids administered for cancer-related indication, systemic antibiotics, PPIs and worse clinical outcomes with PD-1/PD-L1 checkpoint inhibitors, which can be assumed to have immune-modulating detrimental effects.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Cortellini et al. (Sun,) studied this question.

synapsesocial.com/papers/69d74e0cb1cb92dd1bb8a661 https://doi.org/https://doi.org/10.1136/jitc-2020-001361

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients2018 · 38 citations
2Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy2018 · 486 citations
3Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?2013 · 22 citations
4Histamine H2 Receptor-Mediated Suppression of Intestinal Inflammation by Probiotic Lactobacillus reuteri2015 · 168 citations
5Treatment of Elderly Patients With Non–Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology2015 · 72 citations

Me gusta

Guardar

Ver artículo completo